UBS Group’s Indaptus Therapeutics INDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-29,002
| Closed | -$84.4K | – | 10814 |
|
|
2025
Q4 | $84.4K | Buy |
29,002
+28,500
| +5,677% | +$80.9K | ﹤0.01% | 6992 |
|
|
2025
Q3 | $1.44K | Buy |
+502
| New | +$3.62K | ﹤0.01% | 9349 |
|
|
2025
Q2 | – | Sell |
-3
| Closed | -$49 | – | 10533 |
|
|
2025
Q1 | $49 | Sell |
3
-87
| -97% | -$2.01K | ﹤0.01% | 10015 |
|
|
2024
Q4 | $2.12K | Buy |
90
+71
| +374% | +$2.25K | ﹤0.01% | 9105 |
|
|
2024
Q3 | $647 | Sell |
19
-6
| -24% | -$295 | ﹤0.01% | 8856 |
|
|
2024
Q2 | $1.47K | Sell |
25
-44
| -64% | -$2.92K | ﹤0.01% | 8574 |
|
|
2024
Q1 | $4.34K | Sell |
69
-63
| -48% | -$3.35K | ﹤0.01% | 7636 |
|
|
2023
Q4 | $6.51K | Buy |
132
+127
| +2,540% | +$7.99K | ﹤0.01% | 7696 |
|
|
2023
Q3 | $377 | Sell |
5
-18
| -78% | -$1.22K | ﹤0.01% | 8539 |
|
|
2023
Q2 | $1.22K | Buy |
+23
| New | +$1.34K | ﹤0.01% | 7977 |
|
|
2022
Q2 | – | Sell |
-118
| Closed | -$13K | – | 10605 |
|
|
2022
Q1 | $13K | Sell |
118
-58
| -33% | -$7.45K | ﹤0.01% | 8055 |
|
|
2021
Q4 | $28K | Buy |
176
+171
| +3,420% | +$31.8K | ﹤0.01% | 7457 |
|
|
2021
Q3 | $1K | Buy |
+5
| New | +$1.44K | ﹤0.01% | 9193 |
|
|
2021
Q1 | – | Sell |
-7
| Closed | -$3K | – | 9224 |
|
|
2020
Q4 | $3K | Sell |
7
-5
| -42% | -$2.18K | ﹤0.01% | 8005 |
|
|
2020
Q3 | $7K | Sell |
12
-8
| -40% | -$5.88K | ﹤0.01% | 7117 |
|
|
2020
Q2 | $13K | Buy |
20
+4
| +25% | +$2.47K | ﹤0.01% | 6836 |
|
|
2020
Q1 | $7K | Buy |
+16
| New | +$12.1K | ﹤0.01% | 7141 |
|
|
2019
Q4 | – | Sell |
-1
| Closed | -$1.38K | – | 7949 |
|
|
2019
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 7837 |
|
|
2019
Q2 | $5K | Sell |
1
-17
| -94% | -$214K | ﹤0.01% | 7374 |
|
|
2019
Q1 | $290K | Sell |
18
-6
| -25% | -$105K | ﹤0.01% | 4387 |
|
|
2018
Q4 | $398K | Buy |
+24
| New | +$327K | ﹤0.01% | 4438 |
|
|
2018
Q3 | – | Sell |
-11
| Closed | -$105K | – | 8105 |
|
|
2018
Q2 | $104K | Sell |
11
-3
| -21% | -$33.3K | ﹤0.01% | 5409 |
|
|
2018
Q1 | $201K | Buy |
14
+2
| +17% | +$28.3K | ﹤0.01% | 4781 |
|
|
2017
Q4 | $139K | Sell |
12
-2
| -14% | -$31K | ﹤0.01% | 5163 |
|
|
2017
Q3 | $289K | Buy |
+14
| New | +$202K | ﹤0.01% | 4601 |
|
|
2017
Q1 | – | Hold |
0
| – | -$5K | – | 7780 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7240 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | -$12.4K | – | 7200 |
|
|
2016
Q2 | $11K | Hold |
1
| – | – | ﹤0.01% | 6720 |
|
|
2016
Q1 | $12K | Sell |
1
-1
| -50% | -$9.31K | ﹤0.01% | 6541 |
|
|
2015
Q4 | $22K | Buy |
2
+1
| +100% | +$12.8K | ﹤0.01% | 6656 |
|
|
2015
Q3 | $7K | Buy |
+1
| New | +$13.1K | ﹤0.01% | 7502 |
|
Other funds holding INDP
TRCT
SS
UBS Group's INDP Position: Q1 2026 in Review
UBS Group sold out of Indaptus Therapeutics (INDP) in Q1 2026, closing a stake of 29,002 shares — an estimated $84.4K sold.
UBS Group first reported a position in INDP in Q3 2015 and held it in 29 quarters. The position peaked at $398K in Q4 2018. 6 funds tracked by Wall St. Rank hold INDP as of Q1 2026.
- UBS Group reported no remaining Indaptus Therapeutics position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 29,002 Indaptus Therapeutics shares in Q1 2026, an estimated $84.4K.
- UBS Group first reported a position in Indaptus Therapeutics in Q3 2015 and held it in 29 quarters.
- UBS Group's Indaptus Therapeutics position peaked at $398K in Q4 2018.
- 6 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.